 | • レポートコード：MRC2312MG05690 • 出版社/出版日：Market Monitor Global / 2023年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥471,250 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥706,875 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のmRNAワクチン&mRNA医薬品市場規模と予測を収録しています。・世界のmRNAワクチン&mRNA医薬品市場：売上、2018年-2023年、2024年-2029年 ・世界のmRNAワクチン&mRNA医薬品市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のmRNAワクチン&mRNA医薬品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ワクチン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 mRNAワクチン&mRNA医薬品のグローバル主要企業は、Thermo Fisher、 Merck、 Qiagen N.V.、 CureVac、 In-Cell-Art、 eTheRNA、 Takara Bio Inc.、 Sangamo Therapeutics、 Roche CustomBiotech、 BioNTech、 Tiba Biotechnology、 TriLink Bio Technologies、 Argos Therapeutics、 Moderna Therapeutics、 NEB、 Ethris、 Aldevron、 Promega、 Translate Bioなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、mRNAワクチン&mRNA医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のmRNAワクチン&mRNA医薬品市場：タイプ別、2018年-2023年、2024年-2029年 世界のmRNAワクチン&mRNA医薬品市場：タイプ別市場シェア、2022年 ・ワクチン、原薬 世界のmRNAワクチン&mRNA医薬品市場：用途別、2018年-2023年、2024年-2029年 世界のmRNAワクチン&mRNA医薬品市場：用途別市場シェア、2022年 ・感染症、癌 世界のmRNAワクチン&mRNA医薬品市場：地域・国別、2018年-2023年、2024年-2029年 世界のmRNAワクチン&mRNA医薬品市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるmRNAワクチン&mRNA医薬品のグローバル売上、2018年-2023年 ・主要企業におけるmRNAワクチン&mRNA医薬品のグローバル売上シェア、2022年 ・主要企業におけるmRNAワクチン&mRNA医薬品のグローバル販売量、2018年-2023年 ・主要企業におけるmRNAワクチン&mRNA医薬品のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Thermo Fisher、 Merck、 Qiagen N.V.、 CureVac、 In-Cell-Art、 eTheRNA、 Takara Bio Inc.、 Sangamo Therapeutics、 Roche CustomBiotech、 BioNTech、 Tiba Biotechnology、 TriLink Bio Technologies、 Argos Therapeutics、 Moderna Therapeutics、 NEB、 Ethris、 Aldevron、 Promega、 Translate Bio ************************************************************* ・調査・分析レポートの概要 mRNAワクチン&mRNA医薬品市場の定義 市場セグメント 世界のmRNAワクチン&mRNA医薬品市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のmRNAワクチン&mRNA医薬品市場規模 世界のmRNAワクチン&mRNA医薬品市場規模：2022年 VS 2029年 世界のmRNAワクチン&mRNA医薬品市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのmRNAワクチン&mRNA医薬品の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のmRNAワクチン&mRNA医薬品製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ワクチン、原薬 mRNAワクチン&mRNA医薬品のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：感染症、癌 mRNAワクチン&mRNA医薬品の用途別グローバル売上・予測 ・地域別市場分析 地域別mRNAワクチン&mRNA医薬品市場規模 2022年と2029年 地域別mRNAワクチン&mRNA医薬品売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Thermo Fisher、 Merck、 Qiagen N.V.、 CureVac、 In-Cell-Art、 eTheRNA、 Takara Bio Inc.、 Sangamo Therapeutics、 Roche CustomBiotech、 BioNTech、 Tiba Biotechnology、 TriLink Bio Technologies、 Argos Therapeutics、 Moderna Therapeutics、 NEB、 Ethris、 Aldevron、 Promega、 Translate Bio ... |
This research report provides a comprehensive analysis of the mRNA Vaccines and mRNA Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global mRNA Vaccines and mRNA Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of mRNA Vaccines and mRNA Drugs, challenges faced by the industry, and potential opportunities for market players.
The global mRNA Vaccines and mRNA Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The mRNA Vaccines and mRNA Drugs market presents opportunities for various stakeholders, including Infectious Disease, Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in mRNA Vaccines and mRNA Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global mRNA Vaccines and mRNA Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the mRNA Vaccines and mRNA Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the mRNA Vaccines and mRNA Drugs market.
Market Overview: The report provides a comprehensive overview of the mRNA Vaccines and mRNA Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Vaccine, API), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the mRNA Vaccines and mRNA Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the mRNA Vaccines and mRNA Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the mRNA Vaccines and mRNA Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the mRNA Vaccines and mRNA Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the mRNA Vaccines and mRNA Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the mRNA Vaccines and mRNA Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for mRNA Vaccines and mRNA Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the mRNA Vaccines and mRNA Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
mRNA Vaccines and mRNA Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Vaccine
API
Market segment by Application
Infectious Disease
Cancer
Global mRNA Vaccines and mRNA Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Thermo Fisher
Merck
Qiagen N.V.
CureVac
In-Cell-Art
eTheRNA
Takara Bio Inc.
Sangamo Therapeutics
Roche CustomBiotech
BioNTech
Tiba Biotechnology
TriLink Bio Technologies
Argos Therapeutics
Moderna Therapeutics
NEB
Ethris
Aldevron
Promega
Translate Bio
Outline of Major Chapters:
Chapter 1: Introduces the definition of mRNA Vaccines and mRNA Drugs, market overview.
Chapter 2: Global mRNA Vaccines and mRNA Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of mRNA Vaccines and mRNA Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of mRNA Vaccines and mRNA Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global mRNA Vaccines and mRNA Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 mRNA Vaccines and mRNA Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global mRNA Vaccines and mRNA Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global mRNA Vaccines and mRNA Drugs Overall Market Size
2.1 Global mRNA Vaccines and mRNA Drugs Market Size: 2022 VS 2029
2.2 Global mRNA Vaccines and mRNA Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global mRNA Vaccines and mRNA Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top mRNA Vaccines and mRNA Drugs Players in Global Market
3.2 Top Global mRNA Vaccines and mRNA Drugs Companies Ranked by Revenue
3.3 Global mRNA Vaccines and mRNA Drugs Revenue by Companies
3.4 Global mRNA Vaccines and mRNA Drugs Sales by Companies
3.5 Global mRNA Vaccines and mRNA Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 mRNA Vaccines and mRNA Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers mRNA Vaccines and mRNA Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 mRNA Vaccines and mRNA Drugs Players in Global Market
3.8.1 List of Global Tier 1 mRNA Vaccines and mRNA Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 mRNA Vaccines and mRNA Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global mRNA Vaccines and mRNA Drugs Market Size Markets, 2022 & 2029
4.1.2 Vaccine
4.1.3 API
4.2 By Type – Global mRNA Vaccines and mRNA Drugs Revenue & Forecasts
4.2.1 By Type – Global mRNA Vaccines and mRNA Drugs Revenue, 2018-2023
4.2.2 By Type – Global mRNA Vaccines and mRNA Drugs Revenue, 2024-2029
4.2.3 By Type – Global mRNA Vaccines and mRNA Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global mRNA Vaccines and mRNA Drugs Sales & Forecasts
4.3.1 By Type – Global mRNA Vaccines and mRNA Drugs Sales, 2018-2023
4.3.2 By Type – Global mRNA Vaccines and mRNA Drugs Sales, 2024-2029
4.3.3 By Type – Global mRNA Vaccines and mRNA Drugs Sales Market Share, 2018-2029
4.4 By Type – Global mRNA Vaccines and mRNA Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global mRNA Vaccines and mRNA Drugs Market Size, 2022 & 2029
5.1.2 Infectious Disease
5.1.3 Cancer
5.2 By Application – Global mRNA Vaccines and mRNA Drugs Revenue & Forecasts
5.2.1 By Application – Global mRNA Vaccines and mRNA Drugs Revenue, 2018-2023
5.2.2 By Application – Global mRNA Vaccines and mRNA Drugs Revenue, 2024-2029
5.2.3 By Application – Global mRNA Vaccines and mRNA Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global mRNA Vaccines and mRNA Drugs Sales & Forecasts
5.3.1 By Application – Global mRNA Vaccines and mRNA Drugs Sales, 2018-2023
5.3.2 By Application – Global mRNA Vaccines and mRNA Drugs Sales, 2024-2029
5.3.3 By Application – Global mRNA Vaccines and mRNA Drugs Sales Market Share, 2018-2029
5.4 By Application – Global mRNA Vaccines and mRNA Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global mRNA Vaccines and mRNA Drugs Market Size, 2022 & 2029
6.2 By Region – Global mRNA Vaccines and mRNA Drugs Revenue & Forecasts
6.2.1 By Region – Global mRNA Vaccines and mRNA Drugs Revenue, 2018-2023
6.2.2 By Region – Global mRNA Vaccines and mRNA Drugs Revenue, 2024-2029
6.2.3 By Region – Global mRNA Vaccines and mRNA Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global mRNA Vaccines and mRNA Drugs Sales & Forecasts
6.3.1 By Region – Global mRNA Vaccines and mRNA Drugs Sales, 2018-2023
6.3.2 By Region – Global mRNA Vaccines and mRNA Drugs Sales, 2024-2029
6.3.3 By Region – Global mRNA Vaccines and mRNA Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America mRNA Vaccines and mRNA Drugs Revenue, 2018-2029
6.4.2 By Country – North America mRNA Vaccines and mRNA Drugs Sales, 2018-2029
6.4.3 US mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.4.4 Canada mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.4.5 Mexico mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe mRNA Vaccines and mRNA Drugs Revenue, 2018-2029
6.5.2 By Country – Europe mRNA Vaccines and mRNA Drugs Sales, 2018-2029
6.5.3 Germany mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.4 France mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.5 U.K. mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.6 Italy mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.7 Russia mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.8 Nordic Countries mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.5.9 Benelux mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia mRNA Vaccines and mRNA Drugs Revenue, 2018-2029
6.6.2 By Region – Asia mRNA Vaccines and mRNA Drugs Sales, 2018-2029
6.6.3 China mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.6.4 Japan mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.6.5 South Korea mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.6.6 Southeast Asia mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.6.7 India mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America mRNA Vaccines and mRNA Drugs Revenue, 2018-2029
6.7.2 By Country – South America mRNA Vaccines and mRNA Drugs Sales, 2018-2029
6.7.3 Brazil mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.7.4 Argentina mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa mRNA Vaccines and mRNA Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa mRNA Vaccines and mRNA Drugs Sales, 2018-2029
6.8.3 Turkey mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.8.4 Israel mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
6.8.6 UAE mRNA Vaccines and mRNA Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Thermo Fisher
7.1.1 Thermo Fisher Company Summary
7.1.2 Thermo Fisher Business Overview
7.1.3 Thermo Fisher mRNA Vaccines and mRNA Drugs Major Product Offerings
7.1.4 Thermo Fisher mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Thermo Fisher Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck mRNA Vaccines and mRNA Drugs Major Product Offerings
7.2.4 Merck mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Qiagen N.V.
7.3.1 Qiagen N.V. Company Summary
7.3.2 Qiagen N.V. Business Overview
7.3.3 Qiagen N.V. mRNA Vaccines and mRNA Drugs Major Product Offerings
7.3.4 Qiagen N.V. mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Qiagen N.V. Key News & Latest Developments
7.4 CureVac
7.4.1 CureVac Company Summary
7.4.2 CureVac Business Overview
7.4.3 CureVac mRNA Vaccines and mRNA Drugs Major Product Offerings
7.4.4 CureVac mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.4.5 CureVac Key News & Latest Developments
7.5 In-Cell-Art
7.5.1 In-Cell-Art Company Summary
7.5.2 In-Cell-Art Business Overview
7.5.3 In-Cell-Art mRNA Vaccines and mRNA Drugs Major Product Offerings
7.5.4 In-Cell-Art mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.5.5 In-Cell-Art Key News & Latest Developments
7.6 eTheRNA
7.6.1 eTheRNA Company Summary
7.6.2 eTheRNA Business Overview
7.6.3 eTheRNA mRNA Vaccines and mRNA Drugs Major Product Offerings
7.6.4 eTheRNA mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.6.5 eTheRNA Key News & Latest Developments
7.7 Takara Bio Inc.
7.7.1 Takara Bio Inc. Company Summary
7.7.2 Takara Bio Inc. Business Overview
7.7.3 Takara Bio Inc. mRNA Vaccines and mRNA Drugs Major Product Offerings
7.7.4 Takara Bio Inc. mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Takara Bio Inc. Key News & Latest Developments
7.8 Sangamo Therapeutics
7.8.1 Sangamo Therapeutics Company Summary
7.8.2 Sangamo Therapeutics Business Overview
7.8.3 Sangamo Therapeutics mRNA Vaccines and mRNA Drugs Major Product Offerings
7.8.4 Sangamo Therapeutics mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Sangamo Therapeutics Key News & Latest Developments
7.9 Roche CustomBiotech
7.9.1 Roche CustomBiotech Company Summary
7.9.2 Roche CustomBiotech Business Overview
7.9.3 Roche CustomBiotech mRNA Vaccines and mRNA Drugs Major Product Offerings
7.9.4 Roche CustomBiotech mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Roche CustomBiotech Key News & Latest Developments
7.10 BioNTech
7.10.1 BioNTech Company Summary
7.10.2 BioNTech Business Overview
7.10.3 BioNTech mRNA Vaccines and mRNA Drugs Major Product Offerings
7.10.4 BioNTech mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.10.5 BioNTech Key News & Latest Developments
7.11 Tiba Biotechnology
7.11.1 Tiba Biotechnology Company Summary
7.11.2 Tiba Biotechnology Business Overview
7.11.3 Tiba Biotechnology mRNA Vaccines and mRNA Drugs Major Product Offerings
7.11.4 Tiba Biotechnology mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Tiba Biotechnology Key News & Latest Developments
7.12 TriLink Bio Technologies
7.12.1 TriLink Bio Technologies Company Summary
7.12.2 TriLink Bio Technologies Business Overview
7.12.3 TriLink Bio Technologies mRNA Vaccines and mRNA Drugs Major Product Offerings
7.12.4 TriLink Bio Technologies mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.12.5 TriLink Bio Technologies Key News & Latest Developments
7.13 Argos Therapeutics
7.13.1 Argos Therapeutics Company Summary
7.13.2 Argos Therapeutics Business Overview
7.13.3 Argos Therapeutics mRNA Vaccines and mRNA Drugs Major Product Offerings
7.13.4 Argos Therapeutics mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Argos Therapeutics Key News & Latest Developments
7.14 Moderna Therapeutics
7.14.1 Moderna Therapeutics Company Summary
7.14.2 Moderna Therapeutics Business Overview
7.14.3 Moderna Therapeutics mRNA Vaccines and mRNA Drugs Major Product Offerings
7.14.4 Moderna Therapeutics mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Moderna Therapeutics Key News & Latest Developments
7.15 NEB
7.15.1 NEB Company Summary
7.15.2 NEB Business Overview
7.15.3 NEB mRNA Vaccines and mRNA Drugs Major Product Offerings
7.15.4 NEB mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.15.5 NEB Key News & Latest Developments
7.16 Ethris
7.16.1 Ethris Company Summary
7.16.2 Ethris Business Overview
7.16.3 Ethris mRNA Vaccines and mRNA Drugs Major Product Offerings
7.16.4 Ethris mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Ethris Key News & Latest Developments
7.17 Aldevron
7.17.1 Aldevron Company Summary
7.17.2 Aldevron Business Overview
7.17.3 Aldevron mRNA Vaccines and mRNA Drugs Major Product Offerings
7.17.4 Aldevron mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.17.5 Aldevron Key News & Latest Developments
7.18 Promega
7.18.1 Promega Company Summary
7.18.2 Promega Business Overview
7.18.3 Promega mRNA Vaccines and mRNA Drugs Major Product Offerings
7.18.4 Promega mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.18.5 Promega Key News & Latest Developments
7.19 Translate Bio
7.19.1 Translate Bio Company Summary
7.19.2 Translate Bio Business Overview
7.19.3 Translate Bio mRNA Vaccines and mRNA Drugs Major Product Offerings
7.19.4 Translate Bio mRNA Vaccines and mRNA Drugs Sales and Revenue in Global (2018-2023)
7.19.5 Translate Bio Key News & Latest Developments
8 Global mRNA Vaccines and mRNA Drugs Production Capacity, Analysis
8.1 Global mRNA Vaccines and mRNA Drugs Production Capacity, 2018-2029
8.2 mRNA Vaccines and mRNA Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global mRNA Vaccines and mRNA Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 mRNA Vaccines and mRNA Drugs Supply Chain Analysis
10.1 mRNA Vaccines and mRNA Drugs Industry Value Chain
10.2 mRNA Vaccines and mRNA Drugs Upstream Market
10.3 mRNA Vaccines and mRNA Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 mRNA Vaccines and mRNA Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
| 【mRNAワクチン&mRNA医薬品について】 mRNAワクチンやmRNA医薬品は、近年の医療において重要な役割を果たす革新的な技術として注目を集めています。これらの技術は、従来のワクチンや治療法とは異なるアプローチを持ち、効率的で効果的な方法で疾患に対処することが期待されています。本稿では、mRNAワクチンとmRNA医薬品の基本的な概念、特徴、種類、用途、関連技術について探っていきます。 まず、mRNAワクチンについて説明します。mRNAワクチンは、メッセンジャーRNA（mRNA）を利用して、体内で特定のタンパク質を合成させ、免疫応答を引き起こすワクチンです。従来のワクチンでは、弱毒化や不活化されたウイルス、またはウイルスの一部であるタンパク質が用いられるのが一般的でしたが、mRNAワクチンはそのタンパク質の設計図であるmRNAを細胞に直接導入することで、体内で自らそのタンパク質を生成する仕組みを持っています。 mRNAワクチンの主な特徴としては、高い製造効率と迅速な開発が挙げられます。mRNAは合成が比較的容易であり、大量生産が可能です。また、COVID-19パンデミックを契機に、数ヶ月のうちにワクチンの開発が行われ、実用化された例が示すように、従来のワクチンに比べて開発スピードが速い点も大きな利点です。さらに、mRNAワクチンは、ウイルスそのものを体内に導入するわけではないため、感染のリスクが低く、安全性が高いとされています。 mRNAワクチンの用途としては、特にウイルス感染に対する予防が挙げられます。COVID-19に対するワクチンは、その成功例の一つです。ファイザー社やモデルナ社などが開発したmRNAワクチンは、高い有効性と安全性を示し、多くの人々に接種されています。今後は、インフルエンザウイルスやHIV、さらにはさまざまな癌に対するワクチン開発が期待されています。 次に、mRNA医薬品の概念について見ていきます。mRNA医薬品は、mRNAを利用して疾患の治療を行う薬剤です。これには、特定のタンパク質を体内で合成させることで直接的に効果を発揮するものや、遺伝子の発現を調整することで治療効果を狙うものがあります。mRNA医薬品は、特に遺伝子治療や腫瘍免疫療法の分野で期待されています。 mRNA医薬品の特徴として、個別化医療の実現可能性が挙げられます。特定の疾患に対して、患者の遺伝的背景に応じた治療法を提供することができます。また、製造の柔軟性も重要で、多様な疾患に迅速に対応できる点が注目されています。さらに、mRNAを利用した治療法は、従来の小分子薬や抗体薬と比べて、副作用が少ないとされており、安全性の向上が期待されています。 mRNA医薬品の用途は多岐にわたります。たとえば、遺伝性疾患に対する治療法や、がん細胞に特異的な抗原を提示することで腫瘍免疫応答を誘導するための製品があります。がんに対する治療法の中には、がん細胞から発現する新しい抗原をターゲットにしたmRNAワクチンが含まれており、患者ごとに異なる抗原に適応することができます。 関連技術としては、mRNAの安定性向上のための修飾技術や、mRNAを細胞内に効率的に届けるための送達システムが挙げられます。脂質ナノ粒子（LNP）を用いたmRNAの送達技術は、細胞膜を透過しやすくする工夫として広く利用されています。この技術により、mRNAが細胞内に正常に取り込まれることが可能になり、その効果を最大限に引き出すことができます。 また、mRNA研究の進展に伴い、ワクチンや医薬品以外にも、治療法や診断法の新しいアプローチが模索されています。たとえば、mRNAを利用した抗体の生成や、細胞療法における遺伝子改変の手段としての活用が考えられています。さらに、mRNA技術の汎用性は未来の医療に大きな影響を与えると期待されています。 mRNA技術は、新たな医療のパラダイムを形成しつつあります。感染症への迅速な対応、個別化医療の推進、そして新たな治療法の開発を通じて、我々の健康管理の在り方を変革する可能性があります。今後も、mRNAワクチンやmRNA医薬品の研究開発が進むことで、新しい治療法の普及と、さまざまな疾患に対する効果的なアプローチが期待されます。私たちは、この革新的な技術の進展と、それがもたらす未来の医療を見守り、期待していくことが重要です。 |
